The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Approval Alert | Tislelizumab in Metastatic Esophageal Squamous Cell Carcinoma
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
124 Real-World Progression-Free Survival 2 and Tumor Response of CDK4/6is + Aromatase Inhibitor in Patients With HR+/HER2– Metastatic Breast Cancer
2
122 Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC): NATALEE 5-Year Outcomes
3
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
4
121 Five-Year Analysis of Distant Disease-Free Survival (DDFS) Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib (RIB) Plus a Nonsteroidal Aromatase Inhibitor (NSAI) in Patients With HR+/HER2− Early Breast Cancer (EBC)
5